Emma Aitken1, Rachel Kearns2, Lucian Gaianu3, Andrew Jackson4, Mark Steven5, John Kinsella2, Marc Clancy4, Alan Macfarlane2. 1. Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom emmaaitken@nhs.net. 2. Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, United Kingdom. 3. Scottish Health Technologies Group, Healthcare Improvement Scotland, Edinburgh, United Kingdom. 4. Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom. 5. Department of Anaesthesia, Golden Jubilee National Hospital, Clydebank, United Kingdom.
Abstract
BACKGROUND:Regional anesthesia improves short-term blood flow through arteriovenous fistulas (AVFs). We previously demonstrated that, compared with local anesthesia, regional anesthesia improves primary AVF patency at 3 months. METHODS: To study the effects of regional versus local anesthesia on longer-term AVF patency, we performed an observer-blinded randomized controlled trial at three university hospitals in Glasgow, United Kingdom. We randomly assigned 126 patients undergoingprimary radiocephalic or brachiocephalic AVF creation to receive regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine) or local anesthesia (0.5% L-bupivacaine and 1% lidocaine). This report includes findings on primary, functional, and secondary patency at 12 months; reinterventions; and additional access procedures (primary outcome measures were previously reported). We analyzed data by intention to treat, and also performed cost-effectiveness analyses. RESULTS: At 12 months, we found higher primary patency among patients receiving regional versus local anesthesia (50 of 63 [79%] versus 37 of 63 [59%] patients; odds ratio [OR], 2.7; 95% confidence interval [95% CI], 1.6 to 3.8; P=0.02) as well as higher functional patency (43 of 63 [68%] versus 31 of 63 [49%] patients; OR, 2.1; 95% CI, 1.5 to 2.7; P=0.008). In 12 months, 21 revisional procedures, 53 new AVFs, and 50 temporary dialysis catheters were required. Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon. Results were robust after extensive sensitivity and scenario analyses. CONCLUSIONS: Compared with local anesthesia, regional anesthesia significantly improved both primary and functional AVF patency at 1 year and is cost-effective. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Local Anaesthesia versus Regional Block for Arteriovenous Fistulae, NCT01706354.
RCT Entities:
BACKGROUND: Regional anesthesia improves short-term blood flow through arteriovenous fistulas (AVFs). We previously demonstrated that, compared with local anesthesia, regional anesthesia improves primary AVF patency at 3 months. METHODS: To study the effects of regional versus local anesthesia on longer-term AVF patency, we performed an observer-blinded randomized controlled trial at three university hospitals in Glasgow, United Kingdom. We randomly assigned 126 patients undergoing primary radiocephalic or brachiocephalic AVF creation to receive regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine) or local anesthesia (0.5% L-bupivacaine and 1% lidocaine). This report includes findings on primary, functional, and secondary patency at 12 months; reinterventions; and additional access procedures (primary outcome measures were previously reported). We analyzed data by intention to treat, and also performed cost-effectiveness analyses. RESULTS: At 12 months, we found higher primary patency among patients receiving regional versus local anesthesia (50 of 63 [79%] versus 37 of 63 [59%] patients; odds ratio [OR], 2.7; 95% confidence interval [95% CI], 1.6 to 3.8; P=0.02) as well as higher functional patency (43 of 63 [68%] versus 31 of 63 [49%] patients; OR, 2.1; 95% CI, 1.5 to 2.7; P=0.008). In 12 months, 21 revisional procedures, 53 new AVFs, and 50 temporary dialysis catheters were required. Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon. Results were robust after extensive sensitivity and scenario analyses. CONCLUSIONS: Compared with local anesthesia, regional anesthesia significantly improved both primary and functional AVF patency at 1 year and is cost-effective. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Local Anaesthesia versus Regional Block for Arteriovenous Fistulae, NCT01706354.
Authors: David Shemesh; Oded Olsha; Dina Orkin; David Raveh; Ilya Goldin; Yefim Reichenstein; Charles Zigelman Journal: Ultrasound Med Biol Date: 2006-06 Impact factor: 2.998
Authors: Emma Aitken; Andrew Jackson; Rachel Kearns; Mark Steven; John Kinsella; Marc Clancy; Alan Macfarlane Journal: Lancet Date: 2016-08-01 Impact factor: 79.321
Authors: Anton N Sidawy; Richard Gray; Anatole Besarab; Mitchell Henry; Enrico Ascher; Michael Silva; Arnold Miller; Larry Scher; Scott Trerotola; Roger T Gregory; Robert B Rutherford; K Craig Kent Journal: J Vasc Surg Date: 2002-03 Impact factor: 4.268
Authors: B D Bray; J Boyd; C Daly; K Donaldson; A Doyle; J G Fox; A Innes; I Khan; R K Peel; A Severn; I Shilliday; K Simpson; G A Stewart; J Traynor; W Metcalfe Journal: QJM Date: 2012-08-20
Authors: Laura M Dember; Gerald J Beck; Michael Allon; James A Delmez; Bradley S Dixon; Arthur Greenberg; Jonathan Himmelfarb; Miguel A Vazquez; Jennifer J Gassman; Tom Greene; Milena K Radeva; Gregory L Braden; T Alp Ikizler; Michael V Rocco; Ingemar J Davidson; James S Kaufman; Catherine M Meyers; John W Kusek; Harold I Feldman Journal: JAMA Date: 2008-05-14 Impact factor: 56.272
Authors: Alan James Robert Macfarlane; Rachel Joyce Kearns; Emma Aitken; John Kinsella; Marc James Clancy Journal: Trials Date: 2013-08-19 Impact factor: 2.279
Authors: Alan Jr Macfarlane; Rachel J Kearns; Marc James Clancy; David Kingsmore; Karen Stevenson; Andrew Jackson; Patrick Mark; Margaret Aitken; Ramani Moonesinghe; Cecilia Vindrola-Padros; Lucian Gaianu; Gavin Pettigrew; Reza Motallebzadeh; Nikolaos Karydis; Alex Vesey; Rita Singh; Thalakunte Muniraju; Stuart Suttie; Alex McConnachie; Kirsty Wetherall; Kariem El-Boghdadly; Rosemary Hogg; Iain Thomson; Vishal Nangalia; Emma Aitken Journal: BMJ Open Date: 2021-12-22 Impact factor: 2.692
Authors: Patrick Heindel; Peng Yu; Jessica D Feliz; Dirk M Hentschel; Steven K Burke; Mohammed Al-Omran; Deepak L Bhatt; Michael Belkin; C Keith Ozaki; Mohamad A Hussain Journal: Ann Surg Open Date: 2022-08-23